Strategic partnerships Biofidelity is actively expanding its reach through collaborations, such as the integration with CellCarta Group to bring Aspyre Lung assay into broader clinical trial services. This indicates a channel partner strategy that sales can leverage to cross-sell genomic testing capabilities and accelerate adoption in CROs and trial networks.

Product expansion The launch of Aspyre Clinical Test for Liquid Biopsy and the ASPYRE-Lung assay rollout signal a growing product portfolio focused on precision medicine. Sales opportunities include targeting oncology and respiratory genomics segments, as well as institutions seeking clinically validated, lab-developed test solutions.

Geographic footprint With operations and launches in Cambridge, England and Research Triangle Park, North Carolina, Biofidelity demonstrates a transatlantic presence. This opens opportunities for multinational laboratories, hospitals, and networks seeking cross-border genomic testing capabilities and standardized methodologies.

Growth funding A substantial funding level combined with mid-sized revenue suggests room for scale. Business development can target institutional purchasers and grant-funded programs, offering scalable genomic solutions that align with budget cycles and evidence-driven adoption.

Quality and compliance ISO 9001 certification and CLIA-certified laboratory operations underpin trust with buyers. Sales can emphasize rigorous quality management and regulatory readiness to win contracts with hospitals, biopharma sponsors, and research institutions seeking dependable genomic testing partners.